Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $340
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $320 to $340.
Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $320 to $340.